Posters

Oct 2023

ESMO

IKF-s614: INSIGHT 003 evaluating feasibility of eftilagimod alpha (soluble LAG-3) combined with 1st line chemo-immunotherapy in metastatic non-small cell lung cancer (NSCLC) adenocarcinomas – a multicenter early phase trial

Jun 2023

ESMO

Combining the antigen presenting cell activator eftilagimod alpha (soluble LAG 3) and pembrolizumab: overall survival data from the 1st line non-small cell lung carcinoma cohort of TACTI 002

Oct 2023

ESMO

Pembrolizumab in combination with eftilagimod alpha and radiotherapy in neoadjuvant treatment of patients with soft tissue sarcomas – EFTISARC-NEO trial

Jun 2023

ASCO

Final results from TACTI-002 Part C: A Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1

Jun 2023

ASCO

AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic breast cancer patients receiving paclitaxel, following an open-label dose optimization

Publications

Depletion of LAG-3+ T Cells Translated to Pharmacology and Improvement in Psoriasis Disease Activity: A Phase I Randomized Study of mAb GSK2831781

Ellis, Marks, Srinivasan, Barrett, Hopkins, Richards, Fuhr et al. May 2021, Clin. Pharmacol. Ther., 109: 1293-1303. https://doi.org/10.1002/cpt.2091

Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma.

Atkinson V, Khattak A, Haydon A, Eastgate M, Roy A, Prithviraj P, Mueller C, Brignone C, Triebel F. J lmmunother Cancer. 2020 Nov; 8(2):e001681.

Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative Colitis

Slevin, Garner, Lahiff, Tan, Wang, Ferry, Greenaway et al. October 2020 Journal of Crohn’s and Colitis, Volume 14, Issue 10

A LAG-3-Specific Agonist Antibody for the Treatment of T Cell-Induced Autoimmune Diseases.

Angin M, Brignone C, Triebel F. J lmmunol. 2020 Feb 15; 204(4):810-818.

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

Qin, Xu, Yi et al. Molecular Cancer (2019) 18:155 https://doi.org/10.1186/s12943-019-1091-2